ELVN — Enliven Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1672619 ·
Last close
$61.15
Market Cap
$4.48B
52W High
$62.32
52W Low
$33.45
ADV30
937,747
Next earnings
2026-08-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -37,209,000 | -32,485,000 | 910,223,000 | 135,505,000 | 15,074,000 |
| Mar 2026 | 0 | — | -27,823,000 | -23,627,000 | 464,852,000 | 132,184,000 | 11,487,000 |
| Dec 2025 | 0 | — | -34,285,000 | -29,667,000 | 476,168,000 | 98,896,000 | 16,568,000 |
| Sep 2025 | 0 | — | -25,096,000 | -20,148,000 | 490,875,000 | 101,732,000 | 14,753,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-66,939,000
Investing CF
$-390,719,000
Financing CF
$473,726,000
CapEx
$-159,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-403,278,000
Inventory
—
Receivables
—
ST Investments
$759,650,000
EBIT TTM
$-124,413,000
Pretax Income TTM
$-105,927,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -119,658,000 | -103,694,000 | 476,168,000 | 16,568,000 | — | -70,301,000 |
| Dec 2024 | 0 | -104,554,000 | -89,024,000 | 325,760,000 | 15,915,000 | — | -73,192,000 |
| Dec 2023 | 0 | -83,529,000 | -71,584,000 | 271,867,000 | 25,961,000 | — | -61,269,000 |
| Dec 2022 | 0 | -38,791,000 | -37,662,000 | 83,298,000 | 160,123,000 | — | -32,077,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.34
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.27B | $36.18 | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.25B | $38.15 | — |
| DYN | Dyne Therapeutics, Inc. | $4.85B | $25.99 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.86B | $44.72 | — |
News headlines (Yahoo Finance, 1h cache)
Enliven Therapeutics (ELVN) Stock Looks Overvalued As Returns Surge But Book Value Lags
2026-07-04 06:10 · Yahoo
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%
2026-06-27 19:56 · Yahoo
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally
2026-06-27 16:23 · Yahoo
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2026-06-15 20:40 · Yahoo
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
2026-06-13 07:02 · Yahoo
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
2026-06-12 18:22 · Yahoo
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
2026-06-12 02:37 · Yahoo
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-11 20:05 · Yahoo
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN)
2026-06-11 14:36 · Yahoo
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
2026-06-11 13:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.